Skip Navigation



Brain Advance Access published online on December 1, 2004
Brain, doi:10.1093/brain/awh363
© 2004 by Guarantors of Brain
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/1/7    most recent
awh363v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Singh, G.
Right arrow Articles by Sander, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, G.
Right arrow Articles by Sander, J. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received September 9, 2004
Revised November 16, 2004
Accepted November 17, 2004

Invited Review

Cancer risk in people with epilepsy: the role of antiepileptic drugs

Gagandeep Singh 1, Pablo Hernáiz Driever 2, and Josemir W. Sander 1*

1 Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
2 Department of Pediatric Oncology and Hematology, Campus Virchow Hospital, Charité Universitätsmedizin Berlin, Berlin, Germany

* To whom correspondence should be addressed.
Josemir W. Sander, E-mail: l.sander{at}ion.ucl.ac.uk


  Abstract

Summary There has been considerable debate about the relationship between epilepsy and cancer, in particular whether the incidence of cancer is increased in people with epilepsy and whether antiepileptic drugs promote or protect against cancer. We review available evidence from animal experiments, genotoxicity studies and clinico-epidemiological observations, and discuss proposed mechanisms underlying the association between epilepsy and cancer. A carcinoma-promoting effect has been seen unequivocally in rodent models for phenobarbital and phenytoin; phenobarbital promoted liver tumours and phenytoin caused lymphoid cell and liver tumours in rats. Early human epidemiological studies found an association between phenobarbital and hepatocellular carcinoma, and several subsequent studies suggested an association with lung cancer. An association with brain tumours has also been demonstrated. Phenytoin has been causally implicated in three human cancers: lymphoma, myeloma and neuroblastoma, the latter specifically in the setting of foetal hydantoin syndrome. However, despite considerable long-term pharmaco-epidemiological data being available for both antiepileptic drugs, evidence for human carcinogenicity is not consistent and both are considered only possibly carcinogenic to humans. Valproate, however, has been found to exert an antiproliferative effect on certain cancer cell lines both in vitro and in vivo. A corresponding cancer-suppressive effect has not been studied in human epidemiological studies, though there are now preliminary reports of the use of valproate in human haematological and solid tumours. The anticancer activity of valproate appears to be driven by histone deacetylase inhibition and to be independent of hormone or multidrug protein resistance dependant mechanisms. The newer antiepileptic drugs appear to be safe, as no carcinogenicity has been demonstrated either during regulatory testing or in post-marketing surveillance. Nevertheless, the subject of cancers and epilepsy constitutes a promising agenda for clinical and experimental research in the future.

Keywords: epilepsy; cancer; co-morbidity; antiepileptic drugs; carcinogenicity.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Hallas, S. Friis, L. Bjerrum, H. Stovring, S. F. Narverud, T. Heyerdahl, K. Gronbaek, and M. Andersen
Cancer Risk in Long-term Users of Valproate: A Population-Based Case-Control Study
Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1714 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Vandermeers, P. Hubert, P. Delvenne, C. Mascaux, B. Grigoriu, A. Burny, A. Scherpereel, and L. Willems
Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
Clin. Cancer Res., April 15, 2009; 15(8): 2818 - 2828.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
G. Singh, J. H Rees, and J. W Sander
Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment
J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 342 - 349.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Kawai and I. J. Arinze
Valproic Acid-Induced Gene Expression through Production of Reactive Oxygen Species.
Cancer Res., July 1, 2006; 66(13): 6563 - 6569.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C Adelow, A Ahlbom, M Feychting, F Johnsson, J Schwartzbaum, and T Tomson
Epilepsy as a risk factor for cancer.
J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 784 - 786.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.